Table 1.
Demographics and Health Provider Characteristics of AYA Patients by Clinical Trial Enrollment
| Characteristic | Clinical Trial Enrollment |
P | |||||
|---|---|---|---|---|---|---|---|
| Yes |
No |
Unknown |
|||||
| No. | Wt % | No. | Wt % | No. | Wt % | ||
| Total | 191 | 14 | 1,080 | 79.5 | 87 | 6.5 | |
| Cancer type | < .001 | ||||||
| NHL | 30 | 6.4 | 292 | 84.9 | 19 | 8.7 | |
| HL | 43 | 13.2 | 279 | 75.6 | 24 | 11.2 | |
| ALL | 68 | 37.4 | 109 | 57.7 | 10 | 4.9 | |
| Germ cell | 4 | 0.3 | 291 | 88.7 | 23 | 11.0 | |
| Sarcoma | 46 | 32.1 | 109 | 61.9 | 11 | 6.0 | |
| AJCC stage, 6th edition | < .001 | ||||||
| I | 13 | 2.0 | 335 | 83.9 | 29 | 14.1 | |
| II | 44 | 11.8 | 234 | 78.7 | 15 | 9.5 | |
| III | 20 | 10.0 | 140 | 85.8 | 8 | 4.2 | |
| IV | 23 | 11.8 | 155 | 78.7 | 11 | 9.5 | |
| Unknown/NA | 91 | 27.5 | 216 | 65.3 | 24 | 7.2 | |
| Age, years | < .001 | ||||||
| 15-19 | 107 | 34.3 | 167 | 62.0 | 9 | 3.7 | |
| 20-24 | 34 | 8.8 | 230 | 78.8 | 19 | 12.4 | |
| 25-29 | 34 | 3.4 | 231 | 90.1 | 17 | 6.5 | |
| 30-34 | 18 | 5.0 | 226 | 85.1 | 24 | 9.9 | |
| 35-39 | 17 | 3.7 | 226 | 81.6 | 18 | 14.7 | |
| Race/ethnicity | < .001 | ||||||
| Non-Hispanic white | 89 | 8.9 | 491 | 80.5 | 41 | 10.6 | |
| Non-Hispanic black | 29 | 11.2 | 179 | 82.4 | 13 | 6.4 | |
| Hispanic | 54 | 9.7 | 289 | 80.7 | 21 | 9.6 | |
| Asian/Pacific Islander | 18 | 10.4 | 110 | 81.1 | 11 | 8.5 | |
| American Indian/Alaskan Native | 1 | 7.1 | 11 | 85.8 | 1 | 7.1 | |
| Sex | .02 | ||||||
| Male | 111 | 8.3 | 657 | 82.5 | 45 | 9.2 | |
| Female | 80 | 11.9 | 423 | 76.7 | 42 | 11.4 | |
| No. of comorbidities | .32 | ||||||
| 0 | 133 | 9.4 | 738 | 79.8 | 62 | 10.8 | |
| 1 | 36 | 9.5 | 222 | 84.3 | 16 | 6.2 | |
| ≥ 2 | 22 | 9.0 | 120 | 81.3 | 9 | 9.6 | |
| Insurance | < .001 | ||||||
| None | 6 | 3.2 | 122 | 84.2 | 1 | 12.6 | |
| Private | 64 | 13.9 | 239 | 73.0 | 24 | 13.1 | |
| HMO | 73 | 7.3 | 483 | 85.2 | 28 | 7.5 | |
| Any Medicaid | 41 | 14.1 | 199 | 77.6 | 23 | 8.3 | |
| Other/unknown | 7 | 12.7 | 37 | 67.3 | 11 | 20 | |
| Physician specialty | < .001 | ||||||
| Pediatric oncology only | 25 | 70.5 | 11 | 29.5 | 0 | 0 | |
| Hematology/oncology only | 21 | 11.0 | 128 | 82.7 | 7 | 6.3 | |
| Pediatric oncology and other | 71 | 43.3 | 72 | 54.8 | 3 | 1.9 | |
| Hematology/oncology and other | 69 | 6.6 | 660 | 84.4 | 47 | 9.0 | |
| Other specialty only/unknown | 5 | 2.0 | 209 | 85.7 | 30 | 12.3 | |
| Treating hospital size, No. of beds | < .001 | ||||||
| Outpatient | 3 | 11.5 | 24 | 77.6 | 3 | 10.9 | |
| < 200 | 22 | 5.8 | 202 | 82.2 | 21 | 12.0 | |
| 200-299 | 36 | 7.7 | 189 | 79.5 | 18 | 12.8 | |
| 300-399 | 36 | 8.6 | 216 | 78.8 | 17 | 12.6 | |
| ≥ 400 | 91 | 12.4 | 438 | 82.7 | 26 | 4.8 | |
| Unknown | 3 | 33.8 | 9 | 52.9 | 2 | 13.3 | |
| Residency training program | < .001 | ||||||
| Yes | 159 | 12.3 | 713 | 83.2 | 40 | 4.5 | |
| No/unknown | 32 | 5.3 | 367 | 77.4 | 47 | 17.3 | |
Abbreviations: AJCC, American Joint Committee on Cancer; ALL, acute lymphoblastic leukemia; AYA, adolescent and young adult; HL, Hodgkin's lymphoma; HMO, health maintenance organization; NA, not applicable; NHL, Non-Hodgkin's lymphoma; Wt, weighted.